Derek discusses the complexities of running a supplement company versus a compounding pharmacy, highlighting the regulatory hurdles that come with the latter. He emphasizes the importance of controlling the supply chain to maximize margins while questioning whether the effort required for compounding might detract from core business activities. The conversation also touches on the significant market potential for compounding pharmacies, suggesting they could be worth over $100 million.
